background
host
proteas
shown
play
import
role
mani
viral
activ
entri
uncoat
viral
protein
product
diseas
induct
therefor
cellular
proteas
put
target
develop
antivir
inhibit
activ
host
proteas
describ
play
essenti
role
ebola
hcv
hiv
influenza
specif
proteas
inhibitor
abl
reduc
infect
rsv
util
host
proteas
replic
cycl
potenti
antivir
target
unknown
therefor
evalu
effect
proteas
inhibitor
rsv
infect
measur
sensit
rsv
infect
proteas
inhibitor
cell
infect
rsv
incub
h
presenc
absenc
inhibitor
cell
fix
stain
studi
use
fluoresc
microscopi
result
sever
proteas
inhibitor
repres
differ
class
proteas
aebsf
pepstatin
tpck
pmsf
aprotinin
test
inhibitori
effect
rsv
infect
cell
differ
treatment
durat
rang
h
prior
inocul
continu
h
assay
evalu
inhibitor
test
aebsf
tpck
significantli
decreas
rsv
infect
ascertain
observ
effect
aebsf
specif
featur
relat
cell
cell
also
use
similar
almost
complet
block
number
rsv
infect
cell
h
incub
observ
effect
dosedepend
gain
insight
mechan
inhibit
aebsf
treatment
appli
differ
phase
infect
cycl
pre
periand
postinocul
treatment
result
experi
indic
aebsf
mainli
activ
earli
entri
phase
rsv
inhibitori
effect
also
observ
rsv
isol
suggest
gener
featur
rsv
conclus
rsv
infect
inhibit
broad
serin
proteas
inhibitor
aebsf
tpck
confirm
aebsf
inhibit
independ
cell
line
use
rsv
strain
time
point
treatment
inhibitor
potent
found
coincid
expect
moment
entri
virion
host
cell
human
respiratori
syncyti
viru
rsv
princip
viral
caus
seriou
lower
respiratori
tract
infect
lrti
infant
young
children
immunocompromis
cardiopulmonari
diseas
patient
also
elderli
rsv
caus
common
cold
like
symptom
progress
lrti
lead
hospit
signific
morbid
even
mortal
age
three
nearli
children
expos
rsv
least
reinfect
common
throughout
life
rsv
estim
caus
million
lrti
episod
requir
hospit
death
children
year
old
mostli
develop
countri
vaccin
therapeut
current
market
sinc
discoveri
viru
highrisk
prematur
infant
qualifi
receiv
expens
passiv
immun
palivizumab
human
monoclon
antibodi
target
conserv
epitop
rsv
fusion
protein
time
treatment
sever
rsv
diseas
consist
support
care
hydrat
oxygen
rsv
belong
pneumovirida
genu
orthopneumoviru
compris
envelop
virus
negativestrand
rna
genom
kb
genom
nonseg
singl
strand
encod
protein
gene
three
protein
present
envelop
viru
attach
glycoprotein
g
fusion
glycoprotein
f
small
hydrophob
sh
protein
rsv
entri
theoriz
follow
entri
model
paramyxovirus
g
protein
initi
bind
host
cell
interact
gag
follow
fmediat
fusion
host
membran
viral
envelop
allow
viru
entri
locat
rsv
fusion
elucid
sinc
evid
avail
rsv
use
differ
pathway
cell
main
theori
consist
fusion
cell
surfac
entri
endocyt
mechan
macropinocytosi
caveola
endosom
follow
fusion
current
neither
vaccin
antivir
therapi
rsv
approv
avail
commerci
therefor
path
research
discov
altern
antivir
pathway
inhibit
method
view
host
proteas
shown
involv
mani
viral
activ
uncoat
viral
protein
product
posttransl
modif
provid
potenti
antivir
target
use
proteas
inhibitor
advantag
develop
inhibitor
host
protein
gener
reduc
risk
induct
drug
resist
virus
ebola
hcv
hiv
influenza
mer
host
proteas
describ
play
essenti
role
viru
replic
allow
use
specif
proteas
inhibitor
reduc
infect
rsv
well
report
util
host
proteas
replic
cycl
rsv
f
protein
synthes
host
cell
kda
precursor
f
transport
cell
surfac
transgolgi
network
activ
doubl
cleavag
perform
furin
result
two
disulfidelink
membran
anchor
subunit
approxim
kda
f
kda
f
releas
amino
acid
long
peptid
call
enzymat
process
associ
structur
chang
requir
activ
fusogen
f
protein
rsv
g
protein
recent
shown
subject
cleavag
cathepsin
l
endocyt
recycl
vero
cell
result
smaller
size
featur
seem
occur
vero
cell
undoubtedli
process
rsv
replic
cycl
need
enzymat
modif
regul
cellular
host
proteas
may
provid
new
level
control
rsv
infect
leav
host
cellular
metabol
undisturb
use
redund
pathway
studi
analyz
rsv
infect
first
replic
cycl
quantifi
inhibitor
effect
earli
replic
phase
allow
us
character
effect
sever
broad
proteas
inhibitor
earli
infect
replic
rsv
viru
therebi
demonstr
serin
proteas
inhibitor
benzen
sulfonyl
fluorid
hydrochlorid
aebsf
strong
inhibitori
effect
infect
inhibitori
effect
present
aebsf
administ
inocul
cell
observ
effect
laboratori
strain
rsv
well
clinic
isol
immort
cell
line
cell
line
obtain
atcc
cell
gift
dr
ultan
f
power
cell
grown
dulbecco
modifi
eagl
medium
dmem
supplement
inactiv
fetal
bovin
serum
ifb
life
technolog
rsv
refer
strain
clinic
isol
obtain
bei
resourc
propag
cell
briefli
viru
ad
confluent
cell
cultur
small
volum
dmem
left
adher
h
co
afterward
dmem
ifb
ad
obtain
final
concentr
ifb
cultur
left
grow
day
cytopath
effect
cpe
observ
supernat
collect
clear
centrifug
aliquot
snap
frozen
liquid
nitrogen
plaqu
form
unit
pfu
determin
convent
plaqu
assay
describ
schepen
b
et
al
proteas
inhibitor
commerci
avail
purchas
sigmaaldrich
work
concentr
differ
inhibitor
h
prior
infect
cell
cell
cell
seed
concentr
cellsml
black
well
plate
flat
bottom
suitabl
fluoresc
microscopi
greiner
bioon
cell
briefli
wash
dmem
without
ifb
dmem
remov
replac
viru
inoculum
moi
dilut
dmem
without
ifb
left
adher
h
afterward
inoculum
replac
dmem
ifb
cell
incub
h
wash
pb
contain
addit
ca
mg
fix
paraformaldehyd
solut
permeabil
stain
polyclon
goat
antirsv
primari
antibodi
virostat
follow
donkey
antigoat
igg
conjug
alexa
fluor
af
life
technolog
addit
dapi
stain
texa
phalloidin
perform
assay
assess
viru
bind
cell
shape
proteas
inhibitor
ad
cell
specif
time
point
singl
infect
cycl
assay
preinocul
treatment
indic
period
h
inocul
cell
expos
proteas
inhibitor
dilut
dmem
free
ifb
neg
control
nc
incub
dmem
free
ifb
h
dmem
replac
inoculum
without
nc
inhibitor
incub
h
periinoculum
treatment
period
inoculum
remov
replac
dmem
ifb
without
inhibitor
left
stand
overnight
h
wash
perform
period
contain
inhibitor
period
without
inhibitor
bind
kinet
experi
periinoculum
treatment
period
perform
h
follow
warm
dmem
chang
temperatur
shift
remain
postinocul
treatment
period
cell
seed
concentr
cellsml
clear
plate
left
adher
overnight
treat
dilut
seri
inhibitor
h
h
resazurin
ad
well
h
afterward
fluoresc
measur
spectrophotometri
genio
calcul
cc
aebsf
result
cc
mm
imag
obtain
use
axio
observ
invert
microscop
compact
light
sourc
hxp
filter
set
blue
green
red
fluorophor
respect
zeiss
imag
analysi
done
use
imagej
version
initi
calcul
perform
excel
mac
version
afterward
data
transfer
graphpad
prism
analysi
experi
perform
least
triplic
present
percentag
result
number
rsv
posit
cell
total
number
cell
standard
error
mean
sem
result
imag
count
analyz
student
ttest
anova
valu
p
consid
statist
signific
examin
effect
proteas
inhibitor
rsv
infect
singl
replic
cycl
analyz
rsv
infect
immort
cell
line
use
fluoresc
microscopi
singl
infect
cycl
techniqu
consist
inocul
period
h
follow
incub
period
allow
viral
protein
express
second
round
replic
detect
afterward
cell
fix
stain
polyclon
antibodi
pab
antirsv
igg
quantifi
count
number
cell
express
rsv
protein
versu
total
number
nuclei
kinet
experi
rsv
infect
cell
line
allow
us
follow
replic
viru
cell
fluoresc
microscopi
fig
express
viral
protein
cytoplasm
detect
pab
visual
viral
replic
fig
determin
whether
rsv
entri
andor
intracellular
replic
vulner
inhibit
cellular
proteas
determin
impact
commerci
avail
proteas
inhibitor
cystein
peptidas
inhibitor
pepstatin
aspartyl
proteas
inhibitor
aebsf
serin
proteas
inhibitor
tabl
cell
pretreat
inhibitor
h
follow
h
inocul
period
presenc
inhibitor
next
medium
replac
complet
medium
also
contain
inhibitor
cell
incub
addit
h
fix
stain
fluoresc
microscopi
inhibitor
aebsf
show
dose
depend
reduct
infect
nearli
complet
block
rsv
infect
concentr
mm
fig
valid
effect
aebsf
cell
serin
proteas
inhibitor
tpck
mainli
inhibit
chymotrypsinlik
proteas
aprotinin
unabl
pass
cell
membran
help
distinguish
intracellular
extracellular
mode
action
pmsf
less
stabl
variant
aebsf
rapidli
hydrolys
aqueou
solut
tabl
test
capabl
block
rsv
infect
aprotinin
pmsf
treatment
result
signific
decreas
rsv
infect
indic
inhibit
aebsf
probabl
occur
insid
cell
requir
compound
withstand
hydrolysi
long
enough
inhibit
key
host
proteas
tpck
treatment
also
result
decreas
infect
cell
howev
highest
concentr
test
determin
whether
aebsf
also
inhibit
rsv
infect
cell
line
respiratori
tract
origin
frequent
use
rsv
studi
human
lung
carcinoma
transform
human
bronchial
epithelium
fig
cell
plate
pretreat
without
aebsf
h
subject
rsv
infect
h
presenc
absenc
aebsf
inoculum
remov
replac
complet
dmem
without
aebsf
treat
control
condit
respect
cell
incub
h
follow
fixat
stain
analysi
fluoresc
microscopi
nearli
complet
block
rsv
infect
observ
cell
line
concentr
mm
aebsf
fig
well
concentr
depend
effect
mm
aebsf
rsv
infect
decreas
signific
decreas
show
aebsf
inhibit
rsv
infect
uniqu
cell
line
also
observ
cell
well
cell
order
determin
stage
aebsf
treatment
block
rsv
infect
divid
treatment
three
stage
stage
medium
chang
fig
preinocul
treatment
limit
treatment
h
inocul
dmem
without
inactiv
fetal
bovin
serum
ifb
order
block
preexist
activ
proteas
periinocul
treatment
compris
treatment
h
inocul
phase
would
inhibit
proteas
need
attach
fusion
uncoat
postinocul
phase
start
inoculum
remov
h
post
inocul
replac
complet
medium
aebsf
administ
cultur
final
concentr
mm
phase
separ
multipl
phase
timeofaddit
experi
indic
treatment
preinocul
phase
result
signific
decreas
rsv
infect
minor
signific
decreas
observ
periinocul
treatment
postinocul
treatment
well
combin
treatment
compris
preand
periinocul
treatment
treatment
combin
postinocul
phase
either
preor
periinocul
phase
result
larger
signific
decreas
rsv
infect
combin
periand
postinocul
treatment
result
nearli
complet
block
compar
block
observ
earlier
experi
treatment
compris
pre
periand
postinocul
treatment
given
result
hypothes
aebsf
need
present
entri
phase
rsv
order
test
adapt
previou
setup
timeofaddit
experi
inocul
h
induc
synchron
entri
virion
cultur
shift
fig
cell
place
h
prior
rsv
infect
ensur
complet
cool
cultur
cold
inoculum
place
cell
follow
incub
h
allow
attach
viru
afterward
inoculum
remov
cell
wash
cold
medium
remov
unbound
particl
complet
medium
ad
cell
induc
temperatur
shift
cell
incub
h
fix
stain
analyz
fluoresc
microscopi
treatment
periinocul
phase
result
decreas
rsv
infect
consid
normal
sinc
cell
metabol
shut
viru
particl
attach
temperatur
howev
addit
aebsf
temperatur
chang
postinocul
phase
result
signific
decreas
infect
cell
decreas
similar
near
complet
block
observ
aebsf
present
combin
periinocul
postinocul
treatment
result
confirm
previou
result
suggest
aebsf
treatment
rsv
infect
potent
attach
virion
host
cell
start
replic
address
whether
result
would
appli
clinic
isol
well
rsv
lab
strain
test
cultur
infect
rsv
rsv
clinic
isol
sensit
aebsf
treatment
fig
cell
infect
h
presenc
absenc
aebsf
inoculum
remov
replac
complet
dmem
without
aebsf
treat
control
condit
respect
clinic
isol
show
minor
decreas
number
rsv
posit
cell
treat
mm
aebsf
signific
larg
decreas
treat
mm
aebsf
indic
inhibit
probabl
gener
featur
rsv
respiratori
syncyti
viru
rsv
infect
caus
seriou
lower
respiratori
tract
infect
worldwid
affect
mainli
children
elderli
despit
ongo
effort
research
advanc
vaccin
therapeut
market
except
passiv
immunoprophylaxi
avail
highrisk
infant
vast
array
possibl
path
toward
work
therapeut
inhibit
host
proteas
affect
viral
infect
replic
advantag
host
gene
lower
mutat
frequenc
therefor
reduc
risk
acquir
drug
resist
demonstr
rsv
inhibitor
develop
inhibit
host
proteas
may
also
provid
possibl
inhibit
multipl
virus
reli
proteas
replic
cycl
offer
potenti
broadspectrum
antivir
activ
experi
perform
differ
myxovirus
assess
effect
sever
proteas
inhibitor
myxoviru
infect
day
none
found
inhibit
rsv
infect
wherea
sever
inhibit
influenza
virus
b
experi
howev
account
short
term
effect
infect
sinc
mani
compound
evalu
may
limit
halflif
cell
cultur
inhibit
enzym
pool
quickli
replenish
import
address
inhibit
effect
compound
still
activ
therefor
develop
assay
visual
quantifi
one
cycl
rsv
infect
immort
cell
line
h
inocul
use
antibodi
stain
follow
protein
replic
rsv
allow
sensit
detect
potenti
effect
proteas
inhibitor
rsv
infect
singl
infect
cycl
assay
pick
disturb
replic
earli
stage
infect
would
result
decreas
infect
cell
chang
cell
morpholog
easili
detect
count
evalu
number
shape
infect
cell
fluoresc
microscopi
benzen
sulfonyl
fluorid
hydrochlorid
aebsf
broad
serin
proteas
inhibitor
inhibit
proteas
react
hydroxyl
serin
residu
activ
site
form
sulfonyl
deriv
shown
also
reduc
reactiv
oxygen
speci
without
interf
vital
paramet
addit
aebsf
reduc
airway
inflamm
foodallergen
mous
model
cockroachallergen
induc
mous
model
potenti
reduc
airway
inflamm
may
addit
advantag
treatment
rsv
infect
sinc
well
known
rsv
infect
result
skew
immun
respons
character
airway
obstruct
inflamm
experi
found
aebsf
tpck
serin
proteas
inhibitor
capabl
inhibit
rsv
infect
timefram
first
infect
cycl
none
inhibitor
test
consist
inhibitor
differ
proteas
famili
compar
serin
proteas
inhibitor
abl
produc
similar
blockag
rsv
fusion
protein
replic
detect
fluoresc
microscopi
ensur
inhibitori
effect
aebsf
due
inhibit
host
cell
factor
specif
link
one
cell
line
also
test
cell
line
cell
line
aebsf
clearli
inhibit
rsv
infect
similarli
cell
suggest
effect
rsv
infect
aebsf
treatment
specif
one
cell
line
timeofaddit
experi
divid
experi
phase
pretreat
h
periinocul
treatment
h
postinocul
treatment
h
experi
clearli
show
treatment
would
result
near
complet
block
aebsf
present
time
viru
inoculum
pretreat
differ
significantli
nontreat
control
neither
periinocul
treatment
postinocul
treatment
result
signific
decreas
infect
treatment
combin
phase
notabl
decreas
rsv
infect
achiev
combin
treatment
periand
postinocul
treatment
decreas
compar
earlier
experi
treatment
continu
throughout
phase
indic
pretreat
aebsf
effect
rsv
infect
result
lead
us
hypothes
may
fusion
uncoat
compromis
therefor
block
infect
treatment
aebsf
howev
experi
pretreat
cell
effect
infect
indic
cellular
proteas
mediat
fusion
uncoat
yet
present
activ
access
suggest
bind
rsv
need
induc
enzym
activ
block
inhibitor
hypothesi
test
inocul
cell
viru
attach
cell
fuse
also
enzymat
activ
halt
bind
particl
cell
yet
influenc
activ
access
enzym
inhibit
aebsf
afterward
cell
given
warm
medium
incub
induc
fusion
viru
host
cell
well
reactiv
enzymat
process
near
complet
block
rsv
infect
observ
cell
treat
aebsf
start
moment
cell
place
compar
margin
decreas
cell
treat
periinocul
indic
aebsf
potent
moment
temperatur
shift
presum
time
fusion
particl
host
cell
futur
research
would
point
precis
mechan
action
aebsf
rsv
infect
possibl
medic
applic
inhibit
furthermor
combin
effect
aebsf
block
rsv
infect
possibl
reduct
airway
inflamm
may
addit
advantag
search
toward
work
therapeut
rsv
infect
vivo
experi
enlighten
combin
effect
block
rsv
infect
suppress
immun
system
suggest
studi
allergen
model
discov
rsv
infect
inhibit
broad
serin
proteas
inhibitor
benzen
sulfonyl
fluorid
hydrochlorid
aebsf
confirm
effect
inhibit
independ
cell
line
rsv
isol
use
determin
time
point
treatment
inhibitor
potent
found
coincid
expect
moment
fusion
virion
host
cell
result
call
attent
fact
gap
still
remain
knowledg
molecular
entri
process
rsv
indic
import
identifi
proteas
block
aebsf
involv
rsv
entri
replic
addit
mechan
action
need
elucid
addit
inform
may
help
develop
new
therapeut
reduc
burden
caus
rsv
relat
diseas
young
children
elderli
